NCT03821467 Reproducibility of Dual Beam Doppler Fourier-domain Optical Coherence Tomography in Healthy Subjects
| NCT ID | NCT03821467 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Vienna |
| Condition | Ocular Blood Flow |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2018-11-19 |
| Primary Completion | 2025-12-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2018-11-19 with a primary completion date of 2025-12-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Dual beam Doppler Fourier-domain Optical coherence tomography (DOCT) is a noninvasive technique to quantify total retinal blood flow. To enable further development of this technique it is essential to assess short- and long-term reproducibility of DOCT blood flow measurements.
Eligibility Criteria
Inclusion Criteria: * Men and women aged between 18 and 35 years * Non-smokers * Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant * Normal ophthalmic findings, ametropy \< 3 Dpt. Exclusion Criteria: * Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study * Treatment in the previous 3 weeks with any drug (except contraceptives) * Symptoms of a clinically relevant illness in the 3 weeks before the first study day * Blood donation during the previous 3 weeks * Pregnancy, planned pregnancy or lactating * History or family history of epilepsia
Contact & Investigator
Doreen Schmidl, MD, PhD
PRINCIPAL INVESTIGATOR
Medical University of Vienna, Department of Clinical Pharmacology
Frequently Asked Questions
Who can join the NCT03821467 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying Ocular Blood Flow. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03821467 currently recruiting?
Yes, NCT03821467 is actively recruiting participants. Contact the research team at klin-pharmakologie@meduniwien.ac.at for enrollment information.
Where is the NCT03821467 trial being conducted?
This trial is being conducted at Vienna, Austria.
Who is sponsoring the NCT03821467 clinical trial?
NCT03821467 is sponsored by Medical University of Vienna. The principal investigator is Doreen Schmidl, MD, PhD at Medical University of Vienna, Department of Clinical Pharmacology. The trial plans to enroll 20 participants.